A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results
Abstract
Data di Pubblicazione:
2007
Abstract:
The combination of doxorubicin and herceptin (H) has been proven to be an effective regimen in metastatic breast cancer (MBC), although it was associated with an increased risk of cardiotoxicity. Methods: The aim of this study was to evaluate cardiac safety and efficacy of epirubicin (E) in combination with low-dose herceptin (LD-H) as first-line chemotherapy for women with HER-2 positive MBC.
Tipologia CRIS:
1.5 Abstract in rivista
Elenco autori:
DE TURSI, Michele; Carella, C; Ricevuto, E; Gennari, A; Orlandini, C; Frassoldati, A; Conte, Pf; Iacobelli, S.
Link alla scheda completa:
Pubblicato in: